“ Results from ZUMA-1 Cohort 4 demonstrate that early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events while appearing to maintain comparably impressive ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial. Kite Pharma, a pioneer in developing the chimeric antigen receptor (CAR)-T cell treatment ...

-- Unparalleled 44 Percent Estimated Four-Year Overall Survival Rate Among Refractory Large B-cell Lymphoma Patients After a Single Infusion of Yescarta -- -- Findings Support Yescarta as the First ...

A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, ...

Please provide your email address to receive an email when new articles are posted on . Treatment with the anti-PD-L1 antibody atezolizumab after the chimeric antigen receptor T-cell therapy ...

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. This is an ASCO Meeting Abstract from ...